Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992355 | 0.93 | MAOB (0.49) | ALOX15POLBMAOBHIF1AMALT1 | |
| SCHEMBL2995950 | 0.84 | MAOB (0.49) | ALOX15MAOBHIF1AKDM4EALDH1A1 | |
| SCHEMBL2996781 | 0.84 | MAOB (0.59) | MAOBHIF1AMALT1 | |
| SCHEMBL30074599 | 0.83 | ALOX15 (0.56) | ALOX15POLBNPC1RAB9AHPGD | |
| SCHEMBL21531020 | 0.83 | KDM4E (0.58) | ALOX15POLBNPC1RAB9AHPGD | |
| SCHEMBL21531021 | 0.83 | ALOX15 (0.56) | ALOX15POLBNPC1RAB9AHPGD | |
| SCHEMBL30074560 | 0.83 | ALOX15 (0.56) | ALOX15POLBNPC1RAB9AHPGD | |
| SCHEMBL30074583 | 0.83 | ALOX15 (0.56) | ALOX15POLBNPC1RAB9AHPGD | |
| SCHEMBL1674346 | 0.82 | ALDH1A1 (0.63) | POLBRAB9AHPGDMAOBHIF1A | |
| SCHEMBL3000781 | 0.81 | MAOB (0.51) | NPC1RAB9AMAOBHIF1AMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | ALOX15 3350/4885POLB 3173/4885NPC1 4214/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | ALOX15 3350/4885POLB 3173/4885NPC1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.